Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 7/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.51 |
| ▸ | PTGES | O14684 | 4/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 3/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1585161 | 1.00 | HSD17B10 (0.53) | HSD17B10PPARGALOX5PTGESCNR2 | |
| SCHEMBL3875190 | 0.94 | HSD17B10 (0.59) | HSD17B10PPARGALOX5PTGESCNR2 | |
| SCHEMBL31591746 | 0.88 | EPHX1 (0.60) | HSD17B10PPARGALOX5PTGESCNR2 | |
| SCHEMBL11770018 | 0.87 | CYP2C19 (0.50) | HSD17B10PPARGALOX5PTGESEPHX1 | |
| SCHEMBL1858556 | 0.83 | GRIK1 (0.49) | HSD17B10PPARGALOX5PTGESPPARA | |
| SCHEMBL4803842 | 0.82 | HSD17B10 (0.50) | HSD17B10PPARGALOX5PTGESEPHX1 | |
| SCHEMBL22612314 | 0.81 | MAPT (0.50) | HSD17B10PPARGCYP2C19PPARAALDH1A1 | |
| SCHEMBL9107156 | 0.81 | CNR2 (0.47) | PPARGALOX5PTGESCNR2CSNK1E | |
| SCHEMBL7050743 | 0.80 | POLB (0.51) | PPARGALOX5PTGESCYP2C19PPARA | |
| SCHEMBL39018 | 0.80 | ESR1 (0.42) | HSD17B10PPARGALOX5PTGESEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116751199-A | Mitochondrial protease targeted chimera, preparation method and application | 中国科学院基础医学与肿瘤研究所(筹) | 2023-09-15 | — | — | CN | claimed |
| EP-3962917-A1 | METHOD FOR THE MANUFACTURE OF ALKOXYSILYL-CONTAINING THIOCARBOXYLIC ACID ESTERS | Momentive Performance Materials Inc. (US) | 2022-03-09 | — | — | EP | claimed |
| EP-3941453-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING LYMPHOMA USING 6,8-BIS-BENZYLTHIO-OCTANOIC ACID | Rafael Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
| CN-113795499-A | Process for producing alkoxysilyl group-containing thiocarboxylic ester | 迈图高新材料公司 | 2021-12-14 | — | — | CN | claimed |
| EP-3897606-A1 | ORAL THERAPY USING 6,8-BIS-BENZYLTHIO-OCTANOIC ACID | Rafael Pharmaceuticals, Inc. (US) | 2021-10-27 | — | — | EP | claimed |
| CN-112469405-A | Therapeutic methods and compositions for treating pancreatic cancer using 6, 8-bis (benzylthio) octanoic acid | 拉斐尔制药股份有限公司 | 2021-03-09 | — | — | CN | claimed |
| EP-3781148-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING PROSTATE CANCER USING 6,8-BIS-BENZYLTHIO-OCTANOIC ACID | Rafael Pharmaceuticals, Inc. (US) | 2021-02-24 | — | — | EP | claimed |
| US-10919920-B2 | Method for the manufacture of alkoxysilyl-containing thiocarboxylic acid esters | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2021-02-16 | — | — | US | claimed |
| WO-2020223068-A1 | METHOD FOR THE MANUFACTURE OF ALKOXYSILYL-CONTAINING THIOCARBOXYLIC ACID ESTERS | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2020-11-05 | — | — | WO | claimed |
| US-20200347084-A1 | METHOD FOR THE MANUFACTURE OF ALKOXYSILYL-CONTAINING THIOCARBOXYLIC ACID ESTERS | MOMENTIVE PERFORMANCE MATERIALS INC. | 2020-11-05 | — | — | US | claimed |
| WO-2020191144-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING LYMPHOMA USING 6,8-BIS-BENZYLTHIO-OCTANOIC ACID | RAFAEL PHARMACEUTICALS, INC. (US) | 2020-09-24 | — | — | WO | claimed |
| WO-2020132401-A1 | ORAL THERAPY USING 6,8-BIS-BENZYLTHIO-OCTANOIC ACID | RAFAEL PHARMACEUTICALS, INC. (US) | 2020-06-25 | — | — | WO | claimed |
| WO-2019204251-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING PROSTATE CANCER USING 6,8-BIS-BENZYLTHIO-OCTANOIC ACID | RAFAEL PHARMACEUTICALS, INC. (US) | 2019-10-24 | — | — | WO | claimed |
| WO-2011143590-A1 | COMBINATION THERAPY COMPOSITIONS AND METHODS USING LIPOIC ACID DERIVATIVES AND AN ANTI-PROLIFERATION AGENT | CORNERSTONE PHARMACEUTICALS, INC. (US) | 2011-11-17 | — | — | WO | claimed |
| CN-116751199-A | Mitochondrial protease targeted chimera, preparation method and application | 中国科学院基础医学与肿瘤研究所(筹) | 2023-09-15 | — | — | CN | disclosed |
| CN-116710072-A | Therapeutic methods and compositions for treating biliary tract cancers using Devista | 基石制药股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-116669731-A | Therapeutic methods and compositions for treating pancreatic cancer using Devista | 基石制药股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-103044437-A | Amphiphilic conjugate nano-particle for treating tumors, as well as preparation method and application of same | UNIV SHANGHAI JIAOTONG | 2013-04-17 | — | — | CN | disclosed |
| WO-2011143590-A1 | COMBINATION THERAPY COMPOSITIONS AND METHODS USING LIPOIC ACID DERIVATIVES AND AN ANTI-PROLIFERATION AGENT | CORNERSTONE PHARMACEUTICALS, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143593-A1 | CONJUGATES OF A LIPOIC ACID DERIVATIVE AND ANTI-PROLIFERATION AGENT AND MEDICAL USES THEREOF | CORNERSTONE PHARMACEUTICALS, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919920-B2 | Method for the manufacture of alkoxysilyl-containing thiocarboxylic acid esters | TST, MPST, APEH | HSD17B10 323/4885PPARG 3549/4885ALOX5 555/4885 |
| US-20200347084-A1 | METHOD FOR THE MANUFACTURE OF ALKOXYSILYL-CONTAINING THIOCARBOXYLIC ACID ESTERS | TST, MPST, APEH | HSD17B10 323/4885PPARG 3549/4885ALOX5 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.